Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1399372
This article is part of the Research Topic Commercialization and Industrialization in Experimental Pharmacology and Drug Discovery: 2023 View all 7 articles

Deciphering Quinazoline Derivatives' Interactions with EGFR: A Computational Quest for Advanced Cancer Therapy through 3D-QSAR, Virtual Screening, and MD Simulations

Provisionally accepted
Sirajudheen Anwar Sirajudheen Anwar 1*Jowaher Alanazi Jowaher Alanazi 1Nafees Ahemad Nafees Ahemad 2Shafaq Hamza Shafaq Hamza 3Tahir Ali Chohan Tahir Ali Chohan 3Hammad Saleem Hammad Saleem 3*
  • 1 University of Hail, Ha'il, Hail, Saudi Arabia
  • 2 Monash University Malaysia, Subang Jaya, Selangor, Malaysia
  • 3 University of Veterinary and Animal Sciences, Lahore, Punjab, Pakistan

The final, formatted version of the article will be published soon.

    The epidermal growth factor receptor (EGFR) presents a crucial target for combatting cancer mortality. This study employs a suite of computational techniques, including 3D-QSAR, ligandbased virtual screening, molecular docking, fingerprinting analysis, ADME, and DFT-based analyses (MESP, HOMO, LUMO), supplemented by molecular dynamics simulations and MMGB/PBSA free energy calculations, to explore the binding dynamics of quinazoline derivatives with EGFR. With strong q2 and r2 values from CoMFA and CoMSIA models, our 3D-QSAR models reliably predict EGFR inhibitors' efficacy. Utilizing a potent model compound as a reference, an E-pharmacophore model was developed to sift through the eMolecules database, identifying 19 virtual screening hits based on ShapeTanimoto, ColourTanimoto, and TanimotoCombo scores. These hits, assessed via 3D-QSAR, showed pIC50 predictions consistent with experimental data. Our analyses elucidate key features essential for EGFR inhibition, reinforced by ADME studies that reveal favorable pharmacokinetic profiles for most compounds.Among the primary phytochemicals examined, potential EGFR inhibitors were identified. Detailed MD simulation analyses on three select ligands-1Q1, 2Q17, and VS1-demonstrated their stability and consistent interaction over 200 ns, with MM/GBSA values corroborating their docking scores and highlighting 1Q1 and VS1's superior EGFR1 affinity. These results position VS1 as an especially promising lead in EGFR1 inhibitor development, contributing valuable insights towards crafting novel, effective EGFR1 inhibitors.

    Keywords: EGFR, anti-cancer, Virtual Screening, Simulations, 3D-QSAR, In-silico, fingerprinting

    Received: 11 Mar 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 Anwar, Alanazi, Ahemad, Hamza, Chohan and Saleem. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Sirajudheen Anwar, University of Hail, Ha'il, 53962, Hail, Saudi Arabia
    Hammad Saleem, University of Veterinary and Animal Sciences, Lahore, 54000, Punjab, Pakistan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.